Invitae is interested in companies that can contribute positively to its revenues in the next two to three quarters, according to CEO Sean George.
The acquisitions will enable Invitae to add reproductive health genetic testing to its portfolio and become what it calls a "comprehensive genomic information company."
Dubbing itself a "telegenomics company," San Francisco startup Genome Medical announced the launch this week of its genetic consultation services offering.
The company said it now has payor coverage for more than 130 million individuals.
Genome Medical will provide genetic counseling support for Good Start Genetics' VeriYou carrier screening service.
Under the agreement, Roche Diagnostics will offer Good Start's GeneVu carrier screening test along with its Harmony NIPT.
Couples can now buy cystic fibrosis and spinal muscular atrophy carrier screening tests through Amazon, though a doctor will have to approve the order.
The firms found that NGS-based carrier screening is more cost effective than genotyping-based testing for 14 disorders and results in fewer affected births.
The partnerships are in the areas of consumer applications in reproductive health, and genetics-focused educational programs and entrepreneurship support.
Good Start will serve as an in-network laboratory partner for a variety of genetic screening tests.
CNN reports that researchers have tied a new variant to opioid addiction risk.
Organoids derived from patients' tumors may help determine what chemotherapy treatment patients would benefit from, according to New Scientist.
An initiative from GenomeAsia 100K hopes to increase the number of South Asians in genetic research, according to NBC News.
In Science this week: genomic analysis of ancient and modern horses indicates population turnover, and more.